HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.25.
Several analysts have recently commented on HTGM shares. HC Wainwright lowered their target price on shares of HTG Molecular Diagnostics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Canaccord Genuity reiterated a “buy” rating and issued a $3.00 target price on shares of HTG Molecular Diagnostics in a report on Tuesday, August 13th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, August 10th.
Shares of HTGM stock traded up $0.05 on Friday, hitting $1.00. The stock had a trading volume of 245,800 shares, compared to its average volume of 234,865. The business has a 50 day moving average of $1.40 and a 200 day moving average of $2.13. The stock has a market cap of $27.39 million, a price-to-earnings ratio of -1.67 and a beta of 1.55. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.49 and a quick ratio of 3.34. HTG Molecular Diagnostics has a 12-month low of $0.93 and a 12-month high of $5.46.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 6th. The medical research company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $5.80 million during the quarter, compared to analysts’ expectations of $5.54 million. HTG Molecular Diagnostics had a negative net margin of 79.96% and a negative return on equity of 95.77%. As a group, research analysts expect that HTG Molecular Diagnostics will post -0.59 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of HTGM. BlackRock Inc. increased its holdings in HTG Molecular Diagnostics by 16.4% in the 4th quarter. BlackRock Inc. now owns 88,565 shares of the medical research company’s stock worth $225,000 after acquiring an additional 12,448 shares in the last quarter. Geode Capital Management LLC increased its holdings in HTG Molecular Diagnostics by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 217,965 shares of the medical research company’s stock worth $553,000 after acquiring an additional 28,472 shares in the last quarter. Jane Street Group LLC purchased a new stake in HTG Molecular Diagnostics in the 4th quarter worth approximately $27,000. Millennium Management LLC purchased a new stake in HTG Molecular Diagnostics in the 4th quarter worth approximately $151,000. Finally, FMR LLC increased its holdings in HTG Molecular Diagnostics by 0.6% in the 4th quarter. FMR LLC now owns 3,607,849 shares of the medical research company’s stock worth $9,164,000 after acquiring an additional 19,804 shares in the last quarter. Institutional investors own 44.62% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.